Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alliance Pharma, Drug Development Solutions Renamed Resolian | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alliance Pharma, Drug Development Solutions Renamed Resolian

Combines established bioanalytical laboratories and experts in the U.S., U.K., and Australia.

By: Anthony Vecchione

Alliance Pharma, a global provider of bioanalytical, DMPK, and CMC testing services for the pharma and biopharma industry, and Drug Development Solutions, Ltd. will be operating under the new name Resolian, fully integrating the companies into one organization.

The move brings together the companies’ established bioanalytical laboratories and experts in the U.S., U.K., and most recently in Australia, as Resolian continues to expand and support the growing need for small and large molecule bioanalytical and analytical services globally.

“Resolian merges expertise from Alliance Pharma and Drug Development Solutions — two leading providers of bioanalysis and analytical sciences — to continue to deliver world-class solutions across all therapeutic modalities,” said Resolian CEO Patrick Bennett. “Together, we are a global team of experts dedicated to resolving complex challenges and our new name reflects this. Our primary resolution is to continue to support our partners worldwide with an accessible approach, proactive management, and needed innovations in drug development research.”

In a statement, the company said that with an increasing demand for both analytical and bioanalytical solutions in the drug development market, Resolian retains established proximity with its clients in strategic regions while continuing to add global scalability and portability. According to the company, this gives Resolian’s partners the ability to optimize analysis in support of their programs — enabling conduct of early phase development in one location, either Europe, the U.S., or Australia, as well as the capacity for later phase global clinical trials, including rare diseases, oncology, and targeted therapies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics